Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced the granting of non-qualified equity awards to four new employees on March 17, 2023.

Rhea-AI Summary

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced the granting of non-qualified equity awards to four new employees on March 17, 2023. These awards were part of their 2018 Equity Inducement Plan and serve as material inducements for the new hires. In total, options to purchase 63,000 shares of common stock at an exercise price of $0.31 per share were granted, which is equal to the stock's closing price on the grant date. The options will vest over a four-year period, contingent on continued employment. Aeglea focuses on human enzyme therapeutics for rare metabolic diseases and is progressing with its clinical trials for pegtarviliase and pegzilarginase.

Positive

• Granted options to purchase 63,000 shares, signaling recruitment efforts.
• Exercise price set at $0.31, aligning with the current market value.

Negative

• None.

Argus Session date unavailable

-3.72% session move Open Argus

Details

News Market Reaction – AGLE

The recorded move for AGLE in the trading session of this news was -3.72%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AUSTIN, Texas, March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023, as equity inducement awards outside of the company's 2016 Equity Incentive Plan, but under the terms of the company's 2018 Equity Inducement Plan. The awards were granted as material inducements to the employees entering into employment with Aeglea in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules.

The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Aeglea, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Aeglea, pursuant to Nasdaq Listing Rule 5635(c)(4).

The employees received, in the aggregate, options to purchase 63,000 shares of Aeglea's common stock. The options have an exercise price of $0.31 per share, which is equal to the closing price of Aeglea's common stock on March 17, 2023. The option awards vest at 25% of the shares on the one-year anniversary of the grant, with the remainder of the shares vesting ratably over 36 months thereafter subject to each employees' continued employment through the applicable vesting date. The awards are subject to the terms and conditions of the 2018 Equity Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea is investigating pegtarviliase in an ongoing Phase 1/2 clinical trial for the treatment of Classical Homocystinuria. Pegtarviliase has been granted Rare Pediatric Disease Designation. Aeglea's other clinical program, pegzilarginase, achieved the primary endpoint of arginine reduction in the PEACE Phase 3 clinical trial and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Marketing Authorization Application for pegzilarginase is currently under review with the European Medicines Agency. For more information, please visit http://aeglea.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301775360.html

SOURCE Aeglea BioTherapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was announced by Aeglea BioTherapeutics on March 17, 2023?

Aeglea BioTherapeutics announced the granting of non-qualified equity awards to four new employees.

How many shares were granted as options by Aeglea BioTherapeutics?

Aeglea BioTherapeutics granted options to purchase a total of 63,000 shares.

What is the exercise price of the equity awards granted by Aeglea?

The exercise price of the equity awards is $0.31 per share.

What is the purpose of the 2018 Equity Inducement Plan?

The 2018 Equity Inducement Plan is used for granting equity awards to new employees as inducements for joining the company.

What clinical trials is Aeglea BioTherapeutics currently undertaking?

Aeglea is conducting trials for pegtarviliase and pegzilarginase, focusing on rare metabolic diseases.